Your browser doesn't support javascript.
loading
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Lin, Yi; Raje, Noopur S; Berdeja, Jesús G; Siegel, David S; Jagannath, Sundar; Madduri, Deepu; Liedtke, Michaela; Rosenblatt, Jacalyn; Maus, Marcela V; Massaro, Monica; Petrocca, Fabio; Yeri, Ashish; Finney, Olivia; Caia, Andrea; Yang, Zhihong; Martin, Nathan; Campbell, Timothy B; Rytlewski, Julie; Fuller, Jaymes; Hege, Kristen; Munshi, Nikhil C; Kochenderfer, James N.
Afiliación
  • Lin Y; Mayo Clinic, Rochester, MN, USA. lin.yi@mayo.edu.
  • Raje NS; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Berdeja JG; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA.
  • Siegel DS; Hackensack University Medical Center, Hackensack, NJ, USA.
  • Jagannath S; Mount Sinai Medical Center, New York City, NY, USA.
  • Madduri D; Mount Sinai Medical Center, New York City, NY, USA.
  • Liedtke M; Stanford University Medical Center, Palo Alto, CA, USA.
  • Rosenblatt J; Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Maus MV; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Massaro M; 2SeventyBio, Inc, Cambridge, MA, USA.
  • Petrocca F; 2SeventyBio, Inc, Cambridge, MA, USA.
  • Yeri A; 2SeventyBio, Inc, Cambridge, MA, USA.
  • Finney O; 2SeventyBio, Inc, Cambridge, MA, USA.
  • Caia A; Bristol Myers Squibb, Princeton, NJ, USA.
  • Yang Z; Bristol Myers Squibb, Princeton, NJ, USA.
  • Martin N; Bristol Myers Squibb, Princeton, NJ, USA.
  • Campbell TB; Bristol Myers Squibb, Princeton, NJ, USA.
  • Rytlewski J; Bristol Myers Squibb, Princeton, NJ, USA.
  • Fuller J; Bristol Myers Squibb, Princeton, NJ, USA.
  • Hege K; Bristol Myers Squibb, Princeton, NJ, USA.
  • Munshi NC; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Kochenderfer JN; Surgery Branch, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA.
Nat Med ; 29(9): 2286-2294, 2023 09.
Article en En | MEDLINE | ID: mdl-37592106
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Mieloma Múltiple Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Mieloma Múltiple Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos